Work

Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI

Year: 2013

Type: article

Study design: Observational Study

Source: Journal of Thoracic Oncology

DOI: 10.1097/jto.0b013e318294c909

Authors: Mizuki Nishino, Suzanne E. Dahlberg, Stephanie Cardarella, David M. Jackman, Michael S. Rabin, Hiroto Hatabu, Pasi A. Jänne, Bruce E. Johnson

Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Dana-Farber Brigham Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute

Awards: G1702080553, G2645803428, CT Volume Measurement of Lung Cancer treated with Erlotinib: Genomic Correlation, G458608165, SPORE in Lung Cancer, G7495787839, G815073613, G8276505917

OpenAlex ID: W2092147241

FWCI: 3.162

Cites: 56

Cited by: 53

Related to: 10